



Correction to: A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma

Shin-ichi Fuchida¹ · Kazutaka Sunami² · Morio Matsumoto³ · Hirokazu Okumura⁴ · Tohru Murayama⁵ · Toshihiro Miyamoto⁶ · Eichi Otsuka⁷ · Naohito Fujishima⁸ · Tohru Izumi⁹ · Shigehisa Tamaki¹⁰ · Yasushi Hiramatsu¹¹ · Yoshiaki Kuroda¹² · Chihiro Shimazaki¹ · Koichi Akashi⁶ · Mine Harada¹³ · on behalf of the Japan Study Group for Cell Therapy and Transplantation (JSCT)

Published online: 7 November 2018
© The Japanese Society of Hematology 2018

Correction to: International Journal of Hematology
<https://doi.org/10.1007/s12185-018-2543-y>

In the original publication of this article, the “Conflict of interest” was published incorrectly. The corrected “Conflict of interest” is given below for your reading.

Conflict of interest Dr. Sunami reports grants from GlaxoSmithKline, Novartis, Janssen, Sanofi, MSD, Alexion Pharma, Daiichi-Sankyo, and Abbvie, and grants and personal fees from Ono pharmaceutical, Takeda pharmaceutical, Celgene, and Bristol-Myers Squibb. Dr. Matsumoto reports personal fees from Celgene, Janssen, Bristol-Myers Squibb, Ono Pharmaceutical, and Takeda Pharmaceutical. Dr. Okumura reports personal fees from Celgene. Dr. Murayama reports personal fees from Bristol-Myers Squibb,

Celgene, Eisai, Janssen, Kyowa Hakko Kirin, Nippon Shinyaku, Novartis Pharma, Ono Pharmaceutical, Otsuka Pharmaceutical, Pfizer, Sanofi, Siemens Healthcare Diagnostics, Sumitomo Dainippon Pharma, Taiho Pharmaceutical, Takeda Pharmaceutical, Mundipharma, Beckman Coulter, and Chugai Pharmaceutical. Dr. Miyamoto reports personal fees from Celgene. Dr. Shimazaki reports personal fees from Ono Pharmaceutical, Celgene, and Fujimoto Pharmaceutical. Dr. Akashi reports personal fees from Celgene and Janssen, grants from Nippon Kayaku, and grants and personal fees from Kyowa Hakko Kirin, Takeda Pharmaceutical, Shionogi, and Mochida Pharmaceutical. Dr. Harada reports personal fees from Celgene.

The original article can be found online at <https://doi.org/10.1007/s12185-018-2543-y>.

✉ Shin-ichi Fuchida
sfuch0614@gaia.eonet.ne.jp

¹ Department of Hematology, Japan Community Health care Organization Kyoto Kuramaguchi Medical Center, 27 Shimofusa-cho, Kita-ku, Kyoto, Kyoto 603-8151, Japan

² National Hospital Organization Okayama Medical Center, Okayama, Japan

³ National Hospital Organization Nishigunma National Hospital, Shibukawa, Japan

⁴ Toyama Prefectural Central Hospital, Toyama, Japan

⁵ Hyogo Cancer Center, Akashi, Japan

⁶ Kyushu University Hospital, Fukuoka, Japan

⁷ Oita Prefectural Hospital, Oita, Japan

⁸ Akita University Hospital, Akita, Japan

⁹ Tochigi Cancer Center, Utsunomiya, Japan

¹⁰ Ise Red Cross Hospital, Ise, Japan

¹¹ Japanese Red Cross Society Himeji Hospital, Himeji, Japan

¹² Hiroshima University Hospital, Hiroshima, Japan

¹³ Karatsu Higashimatsuura Medical Association, Karatsu, Japan